- Report
- March 2025
- 109 Pages
Global
From €3500EUR$4,214USD£3,180GBP
- Report
- September 2025
- 250 Pages
Global
From €3995EUR$4,490USD£3,507GBP
- Report
- July 2025
- 350 Pages
Global
From €4403EUR$4,949USD£3,865GBP
- Drug Pipelines
- June 2025
- 200 Pages
Global
From €2481EUR$2,789USD£2,178GBP
- Report
- June 2025
- 150 Pages
Global
From €2401EUR$2,699USD£2,108GBP
- Report
- March 2025
- 114 Pages
Global
From €3500EUR$4,214USD£3,180GBP
- Report
- July 2022
- 203 Pages
Global
From €6362EUR$7,150USD£5,584GBP
- Report
- May 2024
- 128 Pages
Global
From €4915EUR$5,524USD£4,314GBP
€5782EUR$6,499USD£5,076GBP
- Report
- May 2024
- 135 Pages
Global
From €4915EUR$5,524USD£4,314GBP
€5782EUR$6,499USD£5,076GBP
- Report
- January 2023
- 124 Pages
From €3070EUR$3,450USD£2,694GBP
- Report
- January 2023
- 134 Pages
Middle East, Africa
From €3070EUR$3,450USD£2,694GBP
- Report
- January 2023
- 160 Pages
Asia Pacific
From €3070EUR$3,450USD£2,694GBP
- Report
- January 2023
- 146 Pages
North America
From €3070EUR$3,450USD£2,694GBP
- Report
- January 2023
- 153 Pages
Europe
From €3070EUR$3,450USD£2,694GBP
- Report
- October 2022
- 209 Pages
Global
From €3959EUR$4,450USD£3,475GBP
- Report
- October 2025
- 50 Pages
Global
From €2358EUR$2,650USD£2,070GBP

Oxybutynin is a drug used to treat symptoms of overactive bladder, a urological disorder. It is an anticholinergic drug, meaning it works by blocking the action of a certain neurotransmitter in the body. Oxybutynin is available in both oral and topical forms, and is often prescribed in combination with other medications. Common side effects include dry mouth, constipation, and blurred vision.
Oxybutynin is one of the most commonly prescribed drugs for urological disorders, and is widely available in both generic and brand name forms. It is often used as a first-line treatment for overactive bladder, and is also used to treat urinary incontinence.
Companies in the Oxybutynin market include Pfizer, Mylan, Teva Pharmaceuticals, and Actavis. Show Less Read more